Meital Portugal
Director of R&D Operations Scinai Immunotherapeutics
Dr. Meital Portugal is an experienced leader in science and technology with a proven track record of driving innovation from concept to commercialization and managing multidisciplinary teams across startup, corporate, and entrepreneurial settings. With a strong background in life sciences and health technology, she brings over 15 years of expertise spanning clinical trials, decision support systems, and skin research, with a focus on developing cutting-edge solutions in biologic therapies and skin care. Dr. Portugal earned her Ph.D. in Pharmacology from the Hebrew University of Jerusalem, School of Pharmacy.
Seminars
Wednesday 20th May 2026
Roundtable Discussion: Strategic Selection of the First Validation Indication for Novel Biologic Formats
11:30 am
- How emerging biologic formats (nanobodies, bispecifics, multi-pathway antibodies) change the logic of indication selection
- When crowded indications like psoriasis or AD make sense as platform-validation settings rather than commercial endpoints
- Trade-offs between rare diseases and common diseases as first-in-human or first-proof-of-concept opportunities
- What level and type of early data regulators and pharma partners actually need to believe in a platform
- Balancing scientific elegance, capital efficiency, CMC risk, and partnering attractiveness in early development decisions
